BioMarin's gene therapy pipeline has had setbacks, including a three-year delay in US approval of Roctavian and stalled development of PKU gene therapy BMN 307 as the Food and Drug Administration ...

Fabry Disease Clinical Trial Pipeline Major pharmaceutical companies are working to advance the pipeline space and unlock the future growth ...

Genzyme has fallen foul of the UK pharma industry code, for making misleading and disparaging claims about a competitor product. AstraZeneca has also been named in advertisements along with the ...

MAR received consulting fees from Biogen, Bristol Myers Squibb, Eli Lilly, Janssen and Roche; and speaker honoraria from Bayer, Biogen, Bristol Myers Squibb, Bromatech, Celgene, Genzyme, Merck ...

Competing interests MR has nothing to disclose. PP received speaker honoraria from Roche, Biogen, Novartis, Merck, Bristol Myers Squibb, Genzyme, Horizon and Sanofi, he has received research support ...